Drugs / Nattokinase
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00447434 | Jun → Oct 2005 | thrombotic disease | Changhua Christian Hospital | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05200234 | Jan 2022 → Jul 2023 | cerebral artery occlusion, cognitive disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| — | NCT00749801 | May 2007 → Mar 2008 | hyperlipidemia | Chi Mei Medical Hospital | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02618148 Background | Jan 2009 → Jun 2015 | — | Trieu, Nguyen Thi, M.D. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nattokinase | “Enzyme nattokinase 300 FU x 24 hours x 28 days” NCT02618148 ↗ |
| Known as | Natto extract | “Natto extract (Nattokinase)” NCT00447434 ↗ |
| Modality | Protein / enzyme biologic | “Nattokinase is a potent fibrinolytic enzyme extracted from Natto.” NCT00447434 ↗ |
| Route | Oral | “subjects will be given nattokinase orally for 8 weeks” NCT00447434 ↗ |